Fate Therapeutics, Inc. (FATE:NASDAQ) closed at $1.79 on October 16, 2026, down 7.01% on the day. The stock trades 44.6% below its 52-week high of $3.23 and 88.4% above its 52-week low of $0.950. Over the past year, it gained 21.8%. Fate Therapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -15.96% | -28.97% | -36.07% | +28.78% | +21.77% |
In 252 trading sessions since October 16, 2025, FATE closed higher on 116 days (46%). Its best day was May 5, 2026 (+31.11%) and its worst was June 3, 2026 (-13.62%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 1 time.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators...
Find more stocks like FATE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.